JPH11513666A5 - - Google Patents

Info

Publication number
JPH11513666A5
JPH11513666A5 JP1997515134A JP51513497A JPH11513666A5 JP H11513666 A5 JPH11513666 A5 JP H11513666A5 JP 1997515134 A JP1997515134 A JP 1997515134A JP 51513497 A JP51513497 A JP 51513497A JP H11513666 A5 JPH11513666 A5 JP H11513666A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997515134A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11513666A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/016122 external-priority patent/WO1997013512A1/en
Publication of JPH11513666A publication Critical patent/JPH11513666A/ja
Publication of JPH11513666A5 publication Critical patent/JPH11513666A5/ja
Ceased legal-status Critical Current

Links

JP9515134A 1995-10-10 1996-10-08 Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤 Ceased JPH11513666A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US521395P 1995-10-10 1995-10-10
US60/005,213 1995-10-10
US1585196P 1996-05-22 1996-05-22
US60/015,851 1996-05-22
PCT/US1996/016122 WO1997013512A1 (en) 1995-10-10 1996-10-08 N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists

Publications (2)

Publication Number Publication Date
JPH11513666A JPH11513666A (ja) 1999-11-24
JPH11513666A5 true JPH11513666A5 (enExample) 2004-10-21

Family

ID=26674078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9515134A Ceased JPH11513666A (ja) 1995-10-10 1996-10-08 Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤

Country Status (9)

Country Link
US (3) US5942536A (enExample)
EP (1) EP0768301B1 (enExample)
JP (1) JPH11513666A (enExample)
AT (1) ATE236122T1 (enExample)
AU (1) AU7261196A (enExample)
CA (1) CA2234166A1 (enExample)
DE (1) DE69627091T2 (enExample)
ES (1) ES2194960T3 (enExample)
WO (1) WO1997013512A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013512A1 (en) * 1995-10-10 1997-04-17 Eli Lilly And Company N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
US5792763A (en) * 1996-10-08 1998-08-11 Eli Lilly And Company Serotonin 5-HT1F agonists
DE69727305T2 (de) * 1996-10-31 2004-06-24 Harbor Branch Oceanographic Institution, Inc., Fort Pierce Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
WO1998047868A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
US6128537A (en) * 1997-05-01 2000-10-03 Medtronic, Inc Techniques for treating anxiety by brain stimulation and drug infusion
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US5905084A (en) * 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
FR2792313A1 (fr) * 1999-04-13 2000-10-20 Synthelabo Derives de 2-aminoethyl-indole, leur preparation et leur application en therapeutique
IL130169A (en) * 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
DE19963178A1 (de) 1999-12-27 2001-07-05 Gruenenthal Gmbh Substituierte Indol-Mannichbasen
EP1377580B1 (en) * 2001-01-30 2006-09-27 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
CA2357114C (en) * 2001-03-22 2010-06-29 Pooger Properties Ltd. Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
JP4264689B2 (ja) * 2001-06-05 2009-05-20 ダイキン工業株式会社 酸の分離方法
CA2463862A1 (en) * 2001-11-16 2003-05-30 Vincent C. Lombardi Method for selective conjugation of analytes to enzymes without unwanted enzyme-enzyme cross-linking
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
JP2006505571A (ja) * 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
WO2004041781A1 (en) * 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones
DE10254596A1 (de) * 2002-11-22 2004-06-03 Merck Patent Gmbh Indolderivate
AU2004232799A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
EP1697305B1 (en) 2003-12-17 2007-08-15 Eli Lilly And Company Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists
US7403118B2 (en) * 2005-11-29 2008-07-22 Checkpoint Systems, Inc. Security device with perimeter alarm
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
ES2570452B1 (es) * 2014-10-15 2017-04-19 Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI829107B (zh) 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US3591603A (en) * 1968-05-13 1971-07-06 Little Inc A 3(3-indole) - lower-alkylamines
US3915990A (en) * 1973-03-13 1975-10-28 Nelson Res & Dev Tryptamines
US3903084A (en) * 1974-02-11 1975-09-02 Upjohn Co Carboximidoyl urea derivatives
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US4544663A (en) * 1984-05-07 1985-10-01 Sandoz, Inc. Indolamine derivatives as anti-fertility agents
US5030640A (en) * 1989-01-05 1991-07-09 Merck & Co., Inc. Novel β-adrenergic agonists and pharmaceutical compositions thereof
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
EP0636623B1 (en) * 1990-06-07 2001-08-16 AstraZeneca AB Indole derivatives as 5-HT1- like agonists
DE4026614A1 (de) * 1990-08-23 1992-02-27 Bayer Ag Phosphonopyrrolidin- und piperidin-haltige pseudopeptide vom statintyp, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel gegen retroviren
US5192770A (en) * 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
TW263508B (enExample) * 1991-02-12 1995-11-21 Pfizer
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
BR9206810A (pt) * 1991-11-25 1995-10-31 Pfizer Derivados de indol
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
TW251284B (enExample) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
DE4321366A1 (de) * 1993-06-26 1995-01-05 Merck Patent Gmbh Piperidine und Piperazine
GB9402680D0 (en) * 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
US5439918A (en) * 1994-03-14 1995-08-08 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5962815A (en) * 1995-01-18 1999-10-05 Prolinx Labs Corporation Antifuse interconnect between two conducting layers of a printed circuit board
WO1997013512A1 (en) * 1995-10-10 1997-04-17 Eli Lilly And Company N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists
US5792763A (en) * 1996-10-08 1998-08-11 Eli Lilly And Company Serotonin 5-HT1F agonists

Similar Documents

Publication Publication Date Title
JP2000500033A5 (enExample)
JP2000500445A5 (enExample)
JP2000500228A5 (enExample)
JP2000500440A5 (enExample)
JP2001517098A5 (enExample)
JPH11506664A5 (enExample)
JP2000500327A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JPH11515034A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JP2000500051A5 (enExample)
JP2000500397A5 (enExample)
JP2000500019A5 (enExample)
JP2000500166A5 (enExample)
JP2001525662A5 (enExample)
JPH11514595A5 (enExample)
JP2000500125A5 (enExample)
JP2000500346A5 (enExample)
JP2000500044A5 (enExample)